Health Canada conditionally approved Leqembi (lecanemab) to treat mild cognitive impairment or dementia due to early ...

Alzheimer’s disease affects every aspect of a person’s being, altering personality and behaviors. A loved one diagnosed with dementia may behave irrationally or rudely toward family members, ...

A single oral dose of methylene blue is able to increase the response of brain regions that control attention and short-term memory, according to University of Texas Health Science Center researchers.

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

Note: An update to this story on Aug. 23, 2021, changed the percentage of assisted living facilities that have incorporated personalized music into their care from 3% to 10%, according to corrected ...

There’s still life to live, however, and friends, family, and caregivers are integral to living the best life possible after a diagnosis. A fourth of all Americans 65 and older who live in communities ...

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) significantly slows cognitive and functional decline in people with early Alzheimer’s disease, according to a new data ...

In the future, doctors may diagnose Alzheimer’s disease by scanning a patient’s eyes — thanks to new evidence that telltale plaques of amyloid-beta are present not only in the brain, but also in the ...

Alzheimer’s disease is the most common cause of dementia, which is a decline in cognitive function, including memory, reasoning, learning, and planning skills. Agitation — abnormal or inappropriate ...

Note: This story was updated Feb. 7, 2023, to correct the number of participants in the Study 201 (NCT01767311), which evaluated Leqembi in 856 people with early Alzheimer’s. Lecanemab (BAN2401), ...

Researchers have found a connection between an infection with the parasite Toxoplasma gondii and neurodegenerative diseases such as Alzheimer’s. The study, “Toxoplasma Modulates Signature Pathways of ...